Shares of HTG Molecular Diagnostics (NASDAQ: HTGM) more than tripled on Friday after the company announced it will host a webinar on the role of RNA profiling in drug discovery and analysis. The presentation will be given by key opinion leader Dr. Robert Spitale of the University of California - Irvine.

Dr. Robert Spitale is an Associate Director and Associate Dean of Research in the School of Pharmacy & Pharmaceutical Sciences at the University of California, Irvine. He has been a faculty member at UCI since 2014 and has been promoted to Professor in 2020. His research focuses on developing chemical and bioinformatic approaches to understand the role of RNA structure and function in normal biology and disease. In addition to his research, Dr. Spitale is involved in the UCI community as the Director of the RNA Club, co-founder of the Chemical and Systems Biology Club, and faculty advisor for the Pharm Sci undergraduate student council. Dr. Spitale received his Ph.D. in Chemistry from the University of Rochester in 2009 and completed postdoctoral studies at Stanford University.

HTG Therapeutics, the company's drug discovery business unit, will also present results from its transcriptome-informed drug discovery process. This approach is being used to design and refine small-molecule chemical libraries and enable the selection of de-risked candidate molecules for potential business development and licensing opportunities in various therapeutic areas.

HTG Molecular Diagnostics is a life science company that uses transcriptome-wide profiling to advance precision medicine. The company's proprietary RNA platform technologies are designed to improve the development of life science tools and diagnostics and enable a differentiated approach to drug discovery. HTG has partnerships with biopharma leaders and academic institutions and has been involved in pioneering innovation for over a decade. The company aims to drive translational research and the development of novel therapeutics and clinical diagnostics across a range of disease areas.

For more information visit www.htgmolecular.com.